Antiretroviral therapy: A key component of a comprehensive HIV prevention strategy

被引：17

作者：

Hull M.W. ^{[1
]}

Montaner J. ^{[1
,2
]}

机构：

[1] Department of Medicine, St Paul's Hospital, University of British Columbia, Vancouver

[2] Division of AIDS, Department of Medicine, University of British Columbia, Vancouver V6Z 1Y6

来源：

Current HIV/AIDS Reports | 2011年 / 8卷 / 2期

关键词：

Antiretroviral therapy; HIV transmission; Mathematical models; Serodiscordant couples; Treatment as prevention;

D O I：

10.1007/s11904-011-0076-6

中图分类号：

学科分类号：

摘要：

Transmission of HIV is critically dependent on the level of HIV viral load within blood and genital secretions. Antiretroviral therapy results in sustained reductions in viral load to undetectable levels. Thus, antiretroviral therapy has long been postulated as a potential means to curb HIV transmission. Observational data have now confirmed that antiretroviral therapy is associated with a decrease in transmission among heterosexual serodiscordant couples, injection-drug users, and in population-based studies. Mathematical models suggest that further expansion of antiretroviral coverage within current guidelines can play a major role in controlling the spread of HIV. Concerns regarding the potential for transmission during acute HIV infection, behavioral disinhibition, and resistance to overcome the impact of treatment on prevention have not materialized to date. The Joint United Nations AIDS (UNAIDS) program has called for the inclusion of antiretroviral treatment as a key pillar in the global strategy to control the spread of HIV infection. © 2011 Springer Science+Business Media, LLC.

引用

页码：85 / 93

页数：8

共 59 条

[1]

Kaposi's Sarcoma and Pneumocystis Pneumonia among Homosexual Men - New York City and California. MMWR, 30, 25, pp. 305-308, (1981)

[2]

UNAIDS. Report on the Global AIDS Epidemic, (2010)

[3]

Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron Jr. J.J., Feinberg J.E., Balfour Jr. H.H., Deyton L.R., Chodakewitz J.A., Fischl M.A., Phair J.P., Spreen W., Pedneault L., Nguyen B.-Y., Cook J.C., A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, New England Journal of Medicine, 337, 11, pp. 725-733, (1997)

[4]

Lohse N., Hansen A.-B.E., Pedersen G., Kronborg G., Gerstoft J., Sorensen H.T., Vaeth M., Obel N., Survival of persons with and without HIV infection in Denmark, 1995-2005, Annals of Internal Medicine, 146, 2, pp. 87-95, (2007)

[5]

Hall H.I., Song R., Rhodes P., Et al., Estimation of HIV incidence in the United States, JAMA, 300, 5, pp. 520-9, (2008)

[6]

Bailey R.C., Moses S., Parker C.B., Agot K., Maclean I., Krieger J.N., Williams C.F., Campbell R.T., Ndinya-Achola J.O., Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial, Lancet, 369, 9562, pp. 643-656, (2007)

[7]

Gray R.H., Kigozi G., Serwadda D., Et al., Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial, Lancet, 369, 9562, pp. 657-66, (2007)

[8]

Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Et al., Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, Science, 329, 5996, pp. 1168-1174, (2010)

[9]

Buchbinder S.P., Mehrotra D.V., Duerr A., Et al., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial, Lancet, 372, 9653, pp. 1881-93, (2008)

[10]

Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand, N Engl J Med, 361, 23, pp. 2209-20, (2009)

← 1 2 3 4 5 6 →